The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.

Throughout the last three months, 12 analysts have evaluated Sarepta Therapeutics (NASDAQ:SRPT), offering a diverse set of opinions from bullish to bearish.The table below provides a concise ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Sarepta Therapeutics (SRPT – Research Report), Intercept Pharma (ICPT – Research Report) and ...

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Detailed price information for Alpha Teknova Inc (TKNO-Q) from The Globe and Mail including charting and trades.

Explore Sarepta Therapeutics analyst ratings and price targets (NASDAQ:SRPT) on Benzinga. Stay updated on expert opinions and forecasts for SRPT stock.

Sarepta Therapeutics (SRPT) closed the last trading session at $143.78, gaining 16.4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets ...

Across the recent three months, 26 analysts have shared their insights on Sarepta Therapeutics (NASDAQ:SRPT), expressing a variety of opinions spanning from bullish to bearish.The table below ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Sarepta Therapeutics (SRPT – Research Report), AlloVir (ALVR – Research Report) and Bristol-Myers Squibb (BMY ...